Press Release: Michele D’Elia and Pierre Côte Join CQDM’s Board of Directors.


Partagez l'article

Press Release: Michele D’Elia and Pierre Côte Join CQDM’s Board of Directors.

MONTREAL, January 12, 2024 – CQDM is proud to announce the appointment of Michele D’Elia, Executive Director, Medical and Scientific Affairs at Roche Diagnostics and Pierre Côte, Global Senior Director for immunology’s new pipeline portfolio at Sanofi to its board of directors.

These additions to the board of directors will bring a depth of experience and a wealth of knowledge to the life sciences sector, thereby consolidating and facilitating biopharmaceutical innovation in Quebec and Canada.

‘’Michele and Pierre are two highly qualified and renowned individuals in our industry. CQDM is very proud to welcome them to our Board of Directors. Their experience will strongly consolidate our desire to facilitate biopharmaceutical innovation in our ecosystem.’’ declared Richard Fazjel, Chairman of the CQDM Board of Directors.

Michele D’Elia joined Roche Diagnostics in 2007 and has held various roles in Regulatory Affairs, Marketing and Business Development. In July 2019, Michele joined the Canadian senior leadership team and is now the Executive Director for Medical and Scientific Affairs. Since April 2023, he also serves as interim Executive Director Access, Policy and Government Relations. In 2022, he was elected as a board member of Medtech Canada and in 2023 was appointed to the Brain-Heart Interconnectome strategic steering committee.

Pierre Côte works at Sanofi US (Cambridge, MA) where he has recently been promoted to Global Senior Director for the immunology new pipeline portfolio. Pierre has worked in the pharmaceutical industry in Canada, in France, and now in United states. Since joining the industry, he has occupied multiple roles in medical affairs, global medical strategy, R&D business strategy, public-private partnership, and innovation management. Before his current role, Pierre helped launch Sanofi’s mRNA Center of Excellence where he was Head of Strategic Partnerships and Innovations for both EU and North America geographies.

-30 –

About CQDM

Facilitator of biopharma innovation

CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, please visit the website:

Media Contact:

Carl Baillargeon

Senior Director – communications and marketing


514 926-9196


Scroll to Top